3 Huge Healthcare Trends and How to Invest in Them (Hint: One Is Marijuana) – Motley Fool

A growing and increasingly longer-living global population makes healthcare one of the most attractive sectors for investors, but I thinkthat genetic research, robotic surgery, and marijuana legalization could be the industry's biggest money-making opportunities. If so, then Illumina Corp.(NASDAQ:ILMN), Intuitive Surgical (NASDAQ:ISRG), and GW Pharmaceuticals (NASDAQ:GWPH) could be smart stocks to buy.

Researchers are increasingly finding that disease is caused by genetic abnormalities, and often, those discoveries are being made using machines and disposable supplies sold by gene-sequencing giant Illumina Corp.

IMAGE SOURCE: GETTY IMAGES.

Illumina is the largest manufacturer of systems used to sequence genetic code, and it's launching new machines this year that could make gene sequencing quicker and cheaper.

There are more than 7,500 of Illumina's machines installed at customers already, and increasing spending on DNA-driven research projects globally, such as precision medicine initiatives in China and the United States, should provide significant revenue and profit tailwinds for years, if not decades.

The company's machines can cost $1 million, or more, but the company really benefits from the ongoing sale of consumables necessary for these machines to operate. As more machines are deployed, revenue for consumables is growing, and since consumables offer more attractive profit margins, that's fueling earnings growth. Since 2011, Illumina's sales and profit have grown by compounded annual rates of 18% and 21%, respectively.

Although the boom-and-bust nature of research budgets means there will be some quarters that are better than other quarters, I believe Illumina's unlikely to lose its dominant position in this market, and if I'm right, then a trend over time toward medicine that aims to correct genetic abnormalities will provide significant opportunities for Illumina to reward investors. The company's newest machines could accelerate that trend, because they could eventually help lower the cost of sequencing genomes from $1,000 today to $100. The NovaSeq 6000, which costs about $1 million, began shipping this quarter.

Good news! Surgery is getting increasingly more precise, and that's reducing recovery times and improving patient outcomes.

At the forefront of this trend is robotics, and when it comes to robotic surgery, there's no better pure-play stock to buy than Intuitive Surgical.

Using research pioneered by DARPA for use on the battlefield, Intuitive Surgical pioneered the development of sophisticated machines that allow surgeons to control robotic arms when performing many surgeries, including prostate and gynecological procedures. Advances in these robotic systems should significantly expand their use in more procedures in the coming decades.

Today, there are almost 4,000 of Intuitive Surgical's da Vinci robotic systems installed at hospitals, and similar to Illumina, the high cost of these machines is only part of the reason I think Intuitive Surgical's going to be a big, long-term winner.

A da Vinci system can cost a hospital $1.5 million, but the average amount spent on replacement instruments and accessories used in operations is especially lucrative. According to management, every da Vinci procedure can produce up to $3,500 in instrument and accessory revenue. That's a lot of margin-friendly revenue when you consider that over 4 million procedures have been performed with these systems, including 750,000 last year alone. Instrument and accessory revenue totaled $1.4 billion, or about 70% of sales, in 2016.

SOURCE: INTUITIVE SURGICAL.

As robotic surgery systems improve, surgeons become more comfortable with them, and as use expands into new areas, such as colorectal surgery and hernia repair, it wouldn't surprise me if Intuitive Surgical's sales and profit march considerably higher over the coming decade.

Overwhelmingly, Americans view on medical marijuana has shifted positive, and as a result, over two dozen U.S. states have passed pro-medical marijuana laws that break down barriers to access.

IMAGE SOURCE: GETTY IMAGES.

While no one knows how a new administration in Washington, D.C. may affect marijuana momentum in the short term, the long-term potential for marijuana to gain ground as a viable alternative medicine is big.

GW Pharmaceuticals could be the drugmaker best positioned to profit from a widespread embrace of medical cannabis. The company's been working on marijuana-based medicines since the 1990s, and it could soon launch its first marijuana derived drug in America.

Last year, GW Pharmaceuticals reported trial results from three separate studies showing that a purified formulation of cannabidiol, or CBD, can reduce the number of seizures experienced monthly by patients with tough-to-treat forms of childhood-onset epilepsy. Specifically, GW Pharmaceuticals showed that patients receiving its Epidiolex experienced about 40% fewer seizures than they did before beginning treatment.

The positive efficacy, plus a safety profile that doesn't seem to be raising eyebrows, suggests that Epidiolex could become an important new drug used by doctors to treat patients who don't respond well to existing epilepsy medications. GW Pharmaceuticals estimates that up to one-third of the 2.2 million epilepsy patients living in the U.S. aren't responding adequately to existing medication.

If the FDA green-lights Epidiolex (management plans to submit an application to the regulator soon), then it can be prescribed by doctors nationwide, regardless of whether medical-marijuana laws have been passed in the doctor's state. That's potentially a huge advantage over medical dispensaries, which only market products without the FDA's blessing in states that have passed laws that are friendly to medical marijuana.

GW Pharmaceuticals isn't stopping its marijuana research with epilepsy, either. The company's studying marijuana cannabinoids in other indications, and while results in the past haven't panned out nearly as well as in epilepsy trials, that doesn't mean programs evaluating it in schizophrenia and autism won't bear fruit.

Because I believe that most Americans will continue supporting access to medical marijuana, and that improving perceptions will remove the stigma associated with its use, the future could prove to be very bright for GW Pharmaceuticals shareholders.

Todd Campbell has no position in any stocks mentioned.His clients may have positions in the companies mentioned.The Motley Fool owns shares of and recommends Illumina and Intuitive Surgical. The Motley Fool has a disclosure policy.

Read more here:
3 Huge Healthcare Trends and How to Invest in Them (Hint: One Is Marijuana) - Motley Fool

New York Rangers Chemistry Threatened by Injuries – Bluelinestation.com

Mar 9, 2017; Raleigh, NC, USA; Carolina Hurricanes forward Valentin Zykov (39) celebrates his first period NHL goal with forward Sebastian Aho (20) and defensemen Brett Pesce (22) against the New York Ranger sat PNC Arena. Mandatory Credit: James Guillory-USA TODAY Sports

New York Rangers: Brendan Smiths Report Card as a Ranger by Timothy Haggerty

On their current road trip, the New York Rangers won two-of-three games despite injuries to important players on the roster. However, the loss of these players has made it difficult for the Rangers to maintain a set lineup.

These shifts to their lines and pairings have threatened the chemistry that the teams worked on all season. It will be essential for the Rangers to run lines as consistently as possible before the start of the postseason.

Both Rick Nash and Michael Grabner are expected to return to the lineup tonight against the Detroit Red Wings.

Nash missed Thursdays game against Carolina with an upper-body injury. He is slated to play tonights game against Detroit with Mika Zibanejad and Pavel Buchnevich.

At points throughout the season, Nash has also played with rookie Jimmy Vesey. With Nashs absence due to injury earlier this year and with Zibanejad jumping around from line-to-line, there has been little consistency for Nash and his linemates.

Michael Grabner has missed five games due to a hip injury. The 29-year-old has been one piece of a key line for the Rangers this year.

Grabners line with J.T. Miller and Kevin Hayes has arguably been one of the most regularly played lines on the roster. Grabner has played some of the best hockey of his career on a line with Miller and Hayes.

Jesper Fast is currently on the Injured Reserved with a shoulder injury. The 24-year-old doesnt score all that much, but Fast is arguably one of the Rangers most prominent forecheckers and adds much needed two-way play on the Rangers fourth line.

Having him back in the lineup in the future will add depth on the Rangers fourth line on both the offensive and defensive end.

On top of the issues the Rangers have faced on defense, they have been impacted by the loss of Dan Girardi and Kevin Klein.

Both Girardi and Klein have been placed on the Injured Reserve and are out indefinitely (Klein for his back and Girardi with an ankle injury). The addition of Brendan Smith, who the Rangers picked up before the trade deadline, and Steven Kampfer, who the Rangers acquired in the Dylan McIlrath trade have kept the Rangers afloat in their absence.

Finally, it was announced yesterday that Henrik Lundqvist would be out for two to three weeks with a lower-body injury. More specifically a muscle strain, this shouldnt be a huge concern for the Rangers, as Lundqvist will be back in time for the playoffs.

Lundqvist is the Rangers most vital piece in the defense. Because the teams most prominent issues stem from their play on the defensive end, they will need Lundqvist to be at his best entering into the playoffs.

In looking ahead, for the Rangers to have any chance moving into the playoffs they need a 100% healthy roster.

With such competitive Metropolitan Division this season, it is vital that the Rangers have every asset on their team at full strength.

They also need to establish some kind of consistency to the lines that they are running.

It seems that head coach Alain Vigneault has been working all season to try and establish what pairings he wants to run on a consistent basis.

He has been changing up combinations in part due to the inevitable injuries the Rangers were bound to face, but has also done it at points when it seems unnecessary. There have also been scenarios where combinations that were effective that were not given the time to fully develop.

While the Rangers players are capable of playing with anyone on the roster, there is a period of adjustment. Additionally, the longer lines are played consistently, the more players will be able to predict their linemates moves on the ice.

Vigneault needs to make a finally call on his lines. He needs to begin to run consistent pairings that are as close to those that will be played in the postseason.

The return of Nash and Grabner to the lineup tonight should be the start in an effort toward these goals of health and consistency on the roster.

More here:
New York Rangers Chemistry Threatened by Injuries - Bluelinestation.com

New Lions CB Hayden has jump start on building chemistry – The Detroit News

Cornerback DJ Hayden will likely compete at both inside and outside cornerback for the Detroit Lions in 2017.(Photo: AP Photo)

Allen Park Chemistry is huge to the success of an NFL secondary, a unit which must be able to quickly communicate and adjust on the fly. The Detroit Lions are returning their entire starting group next season, and new addition, cornerback D.J. Hayden, has a jump start on building the important relationships with his defensive back mates.

Hayden, who officially signed with the Lions on Saturday, worked out with new teammates Darius Slay and Glover Quin during the 2016 offseason and hopes to do so again this year.

Yeah, I talked to both of them, Hayden said. Thats something Im definitely interested in, so we can get our chemistry down. Were a team now. For us to get our chemistry down, it would be great for the team, so we can win some games this year.

Quin, who calls Houston home when not in Detroit, has been known to host teammates for workouts during the offseason. At some point, he got connectedwith Hayden, the area native who also starred for the University of Houston.

A first-round pick in 2013, the same year Slay was selected by the Lions in the second round, the 5-foot-11 Hayden never lived up to his draft status in four years with the Oakland Raiders. But last season, a move inside to cover the slot seemed to get the best out of the fourth-year pro.

Hayden doesnt know how the Lions plan to use him, but hes open to any role in the defensive backfield or on special teams.

Im a fast-twitch guy, Hayden said. Im not the tallest corner in the league, but I feel like I can matchup with any receiver. I can run with anybody. I just want to make plays, work hard and make plays.

Its expected that Hayden will compete with both Nevin Lawson and Quandre Diggs for a starting job.

Moving on to the future, I plan on playing to my max potential, Hayden said.

Follow this link:
New Lions CB Hayden has jump start on building chemistry - The Detroit News

SASSAgate: Anatomy of the Hidden Hand will all be revealed to ConCourt? – Daily Maverick

On Friday afternoon, in response to a PAIA application by DA Shadow Minister of Social Development, Bridget Masango, for information on any new contract between Sassa and CPS, the Department of Social Developments Deputy Information Officer, Michael Machuberg, responded, contract entered into between the department and/or Sassa with Net1/CPS for the distribution of social grants from 01 April 2017 does not exist and therefore not unavailable in our possession.

On March 6, however, Net1 CEO Serge Belamant in an interview with Radio 702 said that the previous week his company had agreed to a set of terms with Sassa on two very, very important issues, one of them were the commercial terms going forward, and the other set of terms is what we were going to do on behalf of Sassa in order for them to take in-house a number of technical processes we currently perform.

So, with only three weeks to go, the entire Sassa social grants crisis still appears to be in legal limbo.

Chief Justice Mogoeng Mogoeng last Wednesday directed Sassa to furnish, by 16:00 on Monday, full details of responsible officials, dates when these officials became aware that the time frames set out by the court could not be met, why the court had not been informed and whether Minister Dlamini had been informed, and if so, when.

Hopefully, whatever it is Sassa and the department and the minister submits to the court will unravel this very thickly woven knot of obfuscation, lies, deceit and delay tactics, and most important, why. Sassa officials and the minister, hopefully, will also answer why they secretly met with President Jacob Zumas lawyer Michael Hulley in December 2016 who then offered legal advice overruling that offered by Advocate Wim Trengove.

One of the officials who is likely to feature in the submission to the ConCourt is Zodwa Mvulane, Sassas Executive Manager, Special Projects. A batch of letters accompanying Belamants affidavit to the ConCourt on March 7 and in response to an application by the Black Sash gives some insight into the anatomy of the train smash.

Timeline and names of officials:

On May 24, 2016, Belamant wrote to Mvulane indicating that he had met with Sassa at your request a few months ago to discuss the implications for Sassa to achieve this objective [of taking the payment in-house]. We discussed both a closed loop system that could permit interoperability with the NPS [National Payments System], as well as an open loop system as is currently provided.

Belamant told Mvulane there is not enough time left between now on March 31, 2017 for the banks to assist in this massive task... As time is running out quite rapidly, it is critical for Sassa to decide on the way forward. In order to prevent disruption in the payment process and to protect beneficiaries, it may be better for Sassa to extend the current CPS contract for at least 12 months, during which Sassa could refine their strategy and implement a phase-out and phase-in plan.

On May 31 Advocate Nazeer Cassim and Mias Mostert advised Sassa that the Constitutional Court would have to be informed of the change in status pertaining to deliverables as well as the possibility of CPS tenure being extended. Meaning that by then Sassa had been aware that it was not going to meet the seven deliverables as set out by the ConCourt.

The court will be especially sensitive in our view to the continued involvement of CPS. Our concern is that the impression might be created that Sassa has all along been pulling the wool over the courts eyes. To prevent this impression from being created, our suggestion is that the change in proposed time frames relating to deliverables be coupled to new information emerging from the meeting with SARB... wrote Cassim and Mostert.

Presenting Sassas annual report to Parliaments portfolio committee on social development on October 13, 2016, where the closing balance of irregular expenditure was revealed as R1-billion and fruitless and wasteful expenditure as R10.9-million, the agency dedicated one paragraph to the institutionalisation of the payment system.

This is planned for implementation in four phases. Phase 0 was the Advisory Committee investigation that took place against the backdrop of the Cash Paymaster Services that ends in March 2017. Phase 1 will be led by Work Stream leaders appointed with the concurrence of the minister to guide the successful implementation of the recommendations of the Advisory Committee for the smooth transition of Sassa towards effectively and efficiently incorporating its payment role to the current in-house functions. Phase 2 and 3 entailing the transition and full roll-out respectively will be implemented during the period April 2017-March 2019.

It was at that presentation, made by then Acting Director-General of the DSD, Dr Wiseman Magasela, that the DAs Bridget Masango first raised the alarm saying that this was a huge project that needed to be undertaken by Sassa and which required a lot of preparation and that involved the lives of 17-million people who were dependent on social grants.

Where is the plan for this project and could the portfolio committee have access to it? Also was Sassa ready to take over the process? asked Masango.

The DAs Lindy Wilson also asked how far the agency was in terms of the seven deliverables as set out by the Constitutional Court.

According to the Parliamentary Monitoring Groups record of the presentation Magasela told the committee that Sassa was ready to give details or reach an agreement of when to come back to the committee to explain progress for the takeover and not withholding any information from the Committee.

Mr Magasela said Sassa was fully aware that the project was a huge one with responsibility in terms of making sure that social grants for 17-million south Africans were fully paid on time as had been the established practice. The Agency was working towards making sure that come March 2017 all south Africans would receive their grants. The Minister was providing political leadership on the issue. There was also a project manager managing this project.

On October 19 the portfolio committee met again to review and adopt the DSD budget and recommendations report. Once again members asked about the progress for Sassas takeover of grant payments.

On November 16 a meeting had been planned for Sassa to brief the portfolio committee but was cancelled at short notice and replaced by a presentation by the National Development Agency.

The minutes read: Members objecting pointed out that the Sassa briefing had been agreed upon as far back as 13 October and had been placed on the agenda following an agreement by the chairperson as far back as June that the plan would be presented to the committee. There was a suggestion that the chairperson had deliberately tried to prevent the presentation, but the chairperson explained that this had in fact happened firstly because the Minister, who wanted to accompany the Sassa delegation, was out of the country, and secondly because Sassa would be meeting with stakeholders prior to coming to brief the committee.

On November 30 Minister Dlamini and Sassa returned to Parliament to brief the committee with regard to Sassas readiness to take over as paymaster for the grants. Present along with Dlamini was the newly-appointed Director-General of the Department of Social Development, Zane Dangor, as well as newly appointed CEO Thokozani Magwaza. At that meeting opposition as well as ANC members complained that the department had not sent the presentation document earlier so that members could read and interrogate it.

At that meeting Magwaza told members that Sassa was ready for the takeover from April 1.

However, SASSA through the minister asked that the committee does not push it to reveal its contingency plans in public as this might jeopardise the work it has done already. What matters is that by 1 April 2017, the grant will be paid. (our italics)

Sassas Executive Manager, Raphaahle Ramokgopa, at that meeting said that Sassa had fulfilled its obligations to the Constitutional Court which had assumed a supervisory role over the agency after the 2012 contract with CPS. The first report, she said had been about the fresh tender application, the second dealing with progress towards implementation of the tender, the third with the outcome of the tender process and the fourth with the implementation process within Sassa.

Ramokgopa admitted that there are areas where Sassa was not meeting deadlines and that the agency had sought a legal opinion.

With the feedback received from legal counsel and other people, Sassa will go back to explain to the court what had happened, the work in progress and the mechanism in place for implementation, said Ramokgopa.

At this presentation is appears as if Ramokgopa parrots some of the content of Belamants May 24 letter to Mvulane.

Heres Ramokgopa on November 30; There are two options. The first is an open architecture or open loop. This involves operating in the national payment system that is provided for by the Reserve Bank. The second option looks into a combination of both an open and closed loop system. Both options specify the need for Sassa account requirements which Sassa has done an expression of interest for. Sassa is also in discussion with the Reserve Bank, PASA and BASA on a specialised account which has limited facilities... The open loop is a system operating in the national payment system, the accounts are fully accessible and allow direct reconciliation. Biometrics is a key factor in both options. In the current payment, the Reserve Bank has given permission to Sassa to utilise biometrics for older people and disabled persons. Discussions are on the way as to whether this can be extended to all beneficiaries. The reason for the need for biometrics is for fraud and risk management. Option 1 requires a new Sassa card that operates in both a closed and open system. It must be an integrated system flexible enough to operate in both and allow cash disbursement for beneficiaries in remote areas. Generally, for both options Sassa needs to develop an internal ICT system, recruit relevant capacity and use a phase in and phase out approach.

Heres Belamant to Mvulane on May 24; We discussed both a closed loop system that could permit interoperability with the NPS, as well as an open loop system as is currently provided. The reason for the two approaches which are both technologically equivalent in terms of interoperability, is that a closed loop system would allow Sassa to provide a payment solution which would be under its control in totality as Sassa would operate only under the Social Assistance Act of 2004. An open system would require Sassa to obtain or make use of a banking licence, amongst others, or to outsource this function to one or more banks resulting in a solution similar to the current system. The open loop payment solution would be governed by the banking rules, the SARB. PASA Visa and MasterCard, the FSB, etc. and, as such, Sassa would not have actually taken the payment function in house in any way but simply outsourced it to a different bank or/and service provider which would probably require a fresh tender to be issued.

At that meeting the DAs Wilson asked whether Sassa had accomplished the ConCourts seven deliverables as well as Who is the supervisor now? Was the court informed when the deliverables were changed? Have the deliverables been extended especially once the deadline for a deliverable has passed? Was the Constitutional Court informed about it and what was the decision?

To which Dangor replied that the fact that some of the timelines have not been met means that Sassa has to go back to the Constitutional Court to discuss the options. The Constitutional Court is the supervisor.

Zodwa Mvulane replied that when Sassa began to solicit advice from other stakeholders as well as reports from the work streams it became apparent that Sassa had been overly ambitious about some of its timelines.

Hence Sassa took the advice and broke down the deliverables and start working on things that matter.

Minister Dlamini then suggested that the committee that it invite officials from Treasury, the Reserve Bank, the Post Office and Postbank so that members could have a clear understanding of what is going on.

However, added Dlamini, there are challenges Sassa cannot talk about.

Back now to Belamant waiting in the wings.

On December 9, 2016 Belamant wrote to Dlamini expressing that he was becoming increasingly concerned with the lack of communication from Sassa and that CPS would also commence the dismantling of its payment infrastructure on January 1, 2017.

Belamant told Dlamini As you are aware, on November 30, 2016, Sassa reported to Parliament that it would be ready to perform the payment of all social grants by April 1, 2017. The Contract and Service Level Agreement (the contracts) between Sassa and Cash Paymaster Services (Pty) Ltd (CPS) were declared invalid by the Constitutional Court of South Africa. The Constitutional Court, however, suspended the declaration of invalidity until a) Sassa issued and awarded a fresh tender or b) until March 31 , 2017 which ever event occurred first.

He added that over the past six months (so at least from August) the SARB, PASA, Grindrod bank and MasterCard have engaged with us to debate the technological issues related to the longevity of the existing Sassa branded cards and if a solution could be found to prolong their lifespan beyond April 1, 2017. He added that these stakeholders were of the view that finding a solution was primordial as Sassa had not finalised or disclosed their transition plan, but that such plan would undoubtedly require the Sassa branded cards to continue to operate beyond April 1, 2017 to ensure that there would be no disruption to the payment of grants service going forward.

And then As a result, we have developed and tested a plan that will ensure continuity but such plan requires your urgent endorsement and commitment.

On December 18 the Sunday Times reported that Minister Dlamini, Dangor, Magwaza, Mvulane and Ramokgopa had met with President Zumas lawyer, Michael Hulley, at the Intercontinental Hotel at OR International Airport. Dlamini had summoned the officials and Hulley had arrived out of the blue.

Dangor and Magwaza reportedly expressed at the meeting their serious concerns with the meddling of Hulley in the matter and also quizzed his role in the matter.

On December 22 Sassas Mvulane responded to CPS saying that it was willing to engage on probabilities for assistance in the transition of Sassa operations towards a new service model, and suggested a first meeting on January 5, 2017.

On December 30 Dlamini chaired a meeting with Sassa CEO, Magwaza, Mvulane, Dlaminis special adviser, Sipho Shezi, DSD deputy director-general Brenton van Vrede, Sassas legal consultant Tim Sukazi, Ramokgopa as well as head of corporate services, Dumisani Ndlovu, at President Zumas lawyer Michael Hulleys office in Durban. There they discussed the CPS contract.

Dangor reportedly refused to attend this meeting.

On February 1 Sassa was back in Parliament for a briefing with the committee, a meeting Dlamini skipped, opting to attend a Cabinet lekgotla instead. Opposition members refused to accept her apology and also complained once again about the late circulation of material to be presented.

ANC committee member Hope Malgas rebuked opposition members saying the lekgotla was important and warranted the postponement of meetings.

There is nothing wrong in postponing. The ANC being in government has to give guidance, said Malgas.

Ramokgopa set out six options including retaining CPS (only snag being the extension of the illegal contract), procuring the services of banks [Treasurys suggestion] while this option may guarantee service delivery, there is no guarantee that beneficiaries will be pa
id who are at the cash pay point, procuring the services of banks and the setting up of a special account [a plan that needed six months], option four using banks for some payouts and CPS for cash pay points, using SAPO and the appointment of a service provider for cash distribution and for banked beneficiaries to use existing accounts.

Given the above circumstances, Sassa came to the conclusion that it has failed. Sassa is of the view that Option 1 carries the least risk in terms of service delivery failure and as such should pursue the option while working on Option 6. In order to pursue this option, Sassa will approach Constitutional Court as a matter of urgency, since this is likely to be virtually the only mechanism to regularise such an approach which would otherwise be irregular. Also procurement in relation to Treasury practice Note 3 of 2016/17 will need to be followed.

It was at this meeting that Magwaza let slip with regard to the fact that Sassas selection of option 1, to go with CPS, had not yet approached the Constitutional Court but that the lawyers have assured Sassa that the court will approve since it is a matter of national emergency.

Which lawyers Magwaza did not disclose.

Was this Hulleys advice?

The ConCourt will soon find out.

On February 2 the Minister of Finance wrote to Dlamini informing her that continuing a contract with CPS would expose government to legal challenges. He proposed that a tender be given to banks and the Post Office.

Sassa revealed what everyone keenly watching developments feared, and suspected: that it was nowhere near ready to assume the critical function and had, in fact, not fulfilled even a single one out of the seven deliverables set out by the Constitutional Court.

If you ask me to choose between irregular [processes] and the country going up in flames, I choose irregular, Thokozani Magwaza told the committee to some audible gasps in the room.

9 February Magwaza wrote to Belamant with regard to exploratory discussions.

16 February Belamant replies to Magwaza stating we have... not received any formal notification from Sassa or yourself regarding the dates for such exploratory discussions. I am concerned that any further delay will significantly impact on our ability to conclude an interim arrangement. It is our view that any negotiations in this respect will require adequate time and consultation to address the following aspects of a new contract. including but not limited to duration, price, phase-in or phase-out strategy, BEE.

Belamant added that it is unlikely that the current contract can be extended due to the Constitutional Court judgment as well as the legal constraints of the PFMA. An extension of the contract would, in any case, be unacceptable to the Net1 board of directors due to the ongoing controversy and reputational damage to our company. I have rescheduled my diary as well as my travel arrangements to accommodate the Sassa meetings and will be available to meet with you from 1 March 2017.

On February 22 the portfolio committee met again. This time the panic was even palpable in the minutes published later by PMG. Dlamini, with CEO Magwaza wiping his brow frequently, dominated the meeting, seldom allowing Sassa officials to speak.

It was the IPFs Liezl Van Der Merwe at the meeting who asked, Can you confirm they [CPS] are seeking an extra R1.3-billion from this department to pay out the social grants? I also want to know that you dont want to pass the buck to Treasury but there are allegations that come March 31 and there is a problem of some sorts you will pass the buck and blame Minister Pravin Gordhan which will give the minister and the president more ammunition to fire Pravin Gordhan.

Committee chair Rose Capa accused the media of terrorising the poor.

On February 28 Sassa appeared before Scopa to account for the mess. It was learned that Magwaza had been booked of ill with high blood pressure and that CEO of the National Development Agency, Thamo Mzobe, had been appointed that morning as acting CEO, and who became ill a week later. Dlamini opted to skip this Scopa meeting, which angered members. It was a shambolic presentation. Members called for Dlamini to account to Scopa.

That same day Sassa filed papers with the Constitutional Court asking it to authorise its engagement with CPS for 12 months from April 1, 2017 to March 30, 2018. Twenty-four hours later Sassa withdrew the application on orders from the minister. Mzobe, who was still on the job at that point, said that Sassa had not been consulted by Magwaza and were now merely sending a follow-up report to the court.

On the same day, the Black Sash files with the Constitutional Court asking the court to act in a supervisory role with regard to the new CPS contract. In court papers the Sash says Sassa breached its constitutional obligations of transparency and accountability to the public to Parliament and to the court.

March 2, 2017 Dlamini and Sassa filed the follow-up report with the ConCourt accepting responsibility for the fiasco.

The minister and Sassa accept responsibility for Sassas inability to deliver the system deliverables set out in the progress report, reads their submission.

Sassa also claimed it only became aware in August and October 2016 after advice from technical advisers that it would be unable to take the payment of social grants in house after March 31. Sassa added it was not ready to move forward due to budget constraints, insufficient internal capacity and a lack of skilled personnel to implement the plan in the time frame it had contemplated.

March 3, 2017 DSD DG Zane Dangor resigns citing a breakdown in the relationship with the minister.

March 5, President Zuma met with Dlamini and Gordhan and said the Sassa crisis is solvable.

March 5 Dlamini and her spokesperson Lumka Oliphant call a last-minute press conference which ends up with Dlamini refusing to answer questions from journalists. Dlamini blamed the media for creating panic with regard to the payment of grants on April 1. Dlamini confirmed however that no deal with CPS had been signed, contradicting an earlier statement that a deal had in fact been concluded.

March 7 Minister Dlamini appears before Scopa and receives a grilling of note. She tells committee members that Scopa had underestimated the amount of work.

March 8 The Chief Justice Mogoeng Mogoeng directs Sassa to reply in detail questions relating to responsible officials, a time line for the fiasco as well as when it was the minister was informed.

March 14 4pm Will all be revealed? DM

Photo: Minister of Social Development Bathabile Dlamini closes the National Youth Camp at 3 South African Infantry Battalion near Kimberley, Northern Cape, 12 December 2016. (Photo: GCIS)

Continue reading here:
SASSAgate: Anatomy of the Hidden Hand will all be revealed to ConCourt? - Daily Maverick

Teen’s Sickle Cell Disease ‘Reversed’ with Groundbreaking Therapy – Reader’s Digest

chairoij/ShutterStockImagine having your spleen removed, undergoing a double hip replacement, and receiving monthly blood transfusions to prevent severe pain attacks, all by the age of 13. That was the life of a teenager in France with sickle cell disease (SCD) until October 2014, when he received experimental gene therapy as part of a clinical study. Now, hes completely off all medications and his SCD is essentially gone, making him the hopeful poster child for the worlds first effective sickle cell disease therapy. (Dont these medical miracles that doctors cant explain.)

Standard treatments were not able to control his SCD symptoms [but] since receiving the stem cell transplant with LentiGlobin, he has been free from severe symptoms and has resumed normal activities, without the need for further transfusions, said study author Marina Cavazzana, MD, PhD, of Necker Hospital in Paris, France, where the trial was conducted, in a news release.

SCD is a inherited blood disorder where sufferers have sickle hemoglobin, an abnormal form of the oxygen-carrying protein which changes the shape of red blood cells (from a flexible disc shape to a rigid crescent one), making it hard for them to pass through blood vessels and often causing blockages that slow or stop the flow of oxygen-rich blood to nearby tissues, causing sudden and severe pain. Sickled red blood cells also die after 10 to 20 days, compared to normal ones which can live up to 120; this can cause the body to have trouble keeping up with red blood cell production, leading to anemia. A stem-cell transplant is currently the only curative option for patients, but fewer than 18 percent of patients are able to find a matching donor.

That is until now. The 13-year-old boy (known as Patient 1204) had bone marrow extracted, which was then genetically altered with the drug LentiGlobin BB305 so that his body made normal, healthy red blood cells instead of the sickle cells it was creating before. After just six months, the proportions of sickled red cells in his blood were significantly lower than those in untreated SCD patients. Now more than 15 months since the treatment, his body is still producing normal red blood cells and he hasnt experience any SCD-related episodes or hospitalizations, according to the study published in the New England Journal of Medicine.

Ive worked in gene therapy for a long time and we make small steps and know theres years more work. But here you have someone who has received gene therapy and has complete clinical remissionthats a huge step forward, Deborah Gill, PhD, of the gene medicine research group at the University of Oxford in England told BBC.

Scientists plan to test the drug on other sickle cell disease patients to see if the results are replicated.

MORE: This Grandmother Beat Cancer in a Groundbreaking 20-Minute Treatment

Read more:
Teen's Sickle Cell Disease 'Reversed' with Groundbreaking Therapy - Reader's Digest

Team USA needs quick spark of chemistry – MLB.com

"I think that a lot of stuff just happens," first baseman Eric Hosmer said of building that chemistry. "A lot of these guys have played against each other through the Minors or with each other when they got to the big leagues. It's not something you can really force the issue on. Hopefully, it'll all just come together when the games start."

The World Baseball Classic runs through March 22. In the U.S., games air live exclusively in English on MLB Network and on an authenticated basis via MLBNetwork.com/watch, while ESPN Deportes and WatchESPN provide the exclusive Spanish-language coverage. MLB.TV Premium subscribers in the U.S. have access to watch every tournament game live on any of the streaming service's 400-plus supported devices. The tournament is being distributed internationally across all forms of television, internet, mobile and radio in territories excluding the U.S., Puerto Rico and Japan. Get tickets for games at Marlins Park, Tokyo Dome, Estadio Charros de Jalisco in Mexico, Petco Park, as well as the Championship Round at Dodger Stadium, while complete coverage -- including schedules, video, stats and gear -- is available at WorldBaseballClassic.com.

Team USA's catchers, Buster Posey of the Giants and Jonathan Lucroy of the Rangers, have the tough task of learning to effectively call games for a staff made up predominantly of short-inning relievers with a varied arsenal of pitches.

"We've had to have a lot of communication. Talking to them in the dugout. Talking to them in the clubhouse so that I can get to know them," Lucroy said. "I know a lot of guys and what they do from facing them. One of the good things about being in the league a decent amount of time is that you know what certain guys want to do against a hitter."

Hosmer and Lucroy are joined by outfielders Adam Jones and Giancarlo Stanton and pitcher Luke Gregerson as the only Classic veterans. All five were members of the 2013 team.

"The will to want to play is a lot from the American players this year, so we are all excited about the chance, and we are going to see what we can do to bring it all home," said Hosmer.

Team USA will face teams that, in some cases, have been practicing as a unit for weeks or more. Most members agreed that the overall talent of this year's squad and the desire to bring the country a Classic title will overcome any unfamiliarity.

"I don't see any weaknesses with this team," said Chris Archer, who will get the start in the opener. "We've got great starters, great relief pitching and great hitters. Everything is a strength with us."

The team didn't exactly show those strengths in a 3-2 loss to the Twins on Wednesday, however. Rockies third baseman Nolan Arenado hit a two-run double in the first inning, but the U.S. was held scoreless by Twins pitchers the rest of the way.

USA@MIN: Arenado drills a two-run double to left

Nolan Arenado drives a two-run double off the left-field wall to open the scoring for Team USA in the top of the 1st inning

Andrew Miller gave up two runs in two-thirds of an inning against the Twins. Gregerson, Jake McGee, Pat Neshek, David Robertson and Nate Jones all tossed a shutout inning before giving way to Twins Minor Leaguers, who pitched the final frames.

J. Scott Butherus is a contributor to MLB.com. This story was not subject to the approval of Major League Baseball or its clubs.

Read this article:
Team USA needs quick spark of chemistry - MLB.com

‘Riverdale’ Star KJ Apa on Betty and Jughead’s ‘Good Chemistry,’ TV Dad Luke Perry And Who Killed Jason Blossom – TooFab

Thursday's episode featured a sneaky Blossom-Cooper showdown that got the entire town searching for Polly Cooper. But possibly even more amusing, Archie (KJ Apa) and Veronica (Camila Mendes) are starting to catch onto Betty (Lili Reinhart) and Jugheads (Cole Sprouse) flirty vibes, which triggered a jealous Archie.

TooFabs Madison Brodsky talked to KJ Apa about Betty and Jugheads flaming relationship, working on set with TV dad Luke Perry and who he thinks actually killed Jason Blossom.

I think Lili and Cole have a lot of good chemistry on-screen and I think it works very well for their characters, Apa told TooFab.

The CW

I dont think so. I think that is just a representation of whatever happened between the two of them before the first episode with that mysterious conflict that lies between their friendship.

As Archie, I think he wants what he cant have and its kind of a weird thing because they totally switched on who likes who. I think he really does show that he likes Betty, but the whole ironic triangle thing is coming back and youll really see it coming in effect soon. As myself, I think Lili and Cole have a lot of good chemistry that you can see on screen and I think it works very well for their characters.

I think they genuinely like each other and I think they are finding something with each other that they can latch onto.

I think you can expect that Jughead will continue to deal with a lot of things from his family to his dad to the murder and youll see that it becomes too much for him so it will spiral into something that shows some amazing acting from Cole and then Jughead eventually breaks.

The CW

I actually wasnt surprised. I knew it. I remember going up to our writer one day and asking, Was it this person? and he looked at me and didnt say anything and laughed so I knew I was right."

Read more:
'Riverdale' Star KJ Apa on Betty and Jughead's 'Good Chemistry,' TV Dad Luke Perry And Who Killed Jason Blossom - TooFab

A new tool for genetically engineering the oldest branch of life – Phys.Org

March 8, 2017 G. William Arends Professor of Microbiology and theme leader of the IGB's Mining Microbial Genomes theme Bill Metcalf, left, with IGB Fellow Dipti Nayak. Credit: University of Illinois at Urbana-Champaign

A new study by G. William Arends Professor of Microbiology at the University of Illinois Bill Metcalf with postdoctoral Fellow Dipti Nayak has documented the use of CRISPR-Cas9 mediated genome editing in the third domain of life, Archaea, for the first time. Their groundbreaking work, reported in Proceedings of the National Academy of Sciences, has the potential to vastly accelerate future studies of these organisms, with implications for research including global climate change. Metcalf and Nayak are members of the Carl R. Woese Institute for Genomic Biology at Illinois.

"Under most circumstances our model archaeon, Methanosarcina acetivorans, has a doubling time of eight to ten hours, as compared to E. coli, which can double in about 30 minutes. What that means is that doing genetics, getting a mutant, can take monthsthe same thing would take three days in E. coli," explains Nayak. "What CRISPR-Cas9 enables us to do, at a very basic level, is speed up the whole process. It removes a major bottleneck... in doing genetics research with this archaeon.

"Even more," continues Nayak, "with our previous techniques, mutations had to be introduced one step at a time. Using this new technology, we can introduce multiple mutations at the same time. We can scale up the process of mutant generation exponentially with CRISPR."

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, began as an immune defense system in archaea and bacteria. By identifying and storing short fragments of foreign DNA, Cas (CRISPR-associated system) proteins are able to quickly identify that DNA in the future, so that it can then quickly be destroyed, protecting the organism from viral invasion.

Since its discovery, a version of this immune systemCRISPR-Cas9has been modified to edit genomes in the lab. By pairing Cas9 with a specifically engineered RNA guide rather than a fragment of invasive DNA, the CRISPR system can be directed to cut a cell's genome in an arbitrary location such that existing genes can be removed or new ones added. This system has been prolifically useful in editing eukaryotic systems from yeast, to plant, to fish and even human cells, earning it the American Association for the Advancement of Science's 2015 Breakthrough of the Year award. However, its implementation in prokaryotic species has been met with hurdles, due in part to their different cellular processes.

To use CRISPR in a cellular system, researchers have to develop a protocol that takes into account a cell's preferred mechanism of DNA repair: after CRISPR's "molecular scissors" cut the chromosome, the cell's repair system steps in to mend the damage through a mechanism that can be harnessed to remove or add additional genetic material. In eukaryotic cells, this takes the form of Non-Homologous End Joining (NHEJ). Though this pathway has been used for CRISPR-mediated editing, it has the tendency to introduce genetic errors during its repair process: nucleotides, the rungs of the DNA ladder, are often added or deleted at the cut site.

NHEJ is very uncommon in prokaryotes, including Archaea; instead, their DNA is more often repaired through a process known as homology-directed repair. By comparing the damage to a DNA template, homology-directed repair creates what Nayak calls a "deterministic template"the end result can be predicted in advance and tailored to the exact needs of the researcher.

In many ways, homology-directed repair is actually preferable for genome editing: "As much as we want CRISPR-Cas9 to make directed edits in eukaryotic systems, we often end up with things that we don't want, because of NHEJ," explains Nayak. "In this regard, it was a good thing that most archaeal strains don't have a non-homologous end joining repair system, so the only way DNA can be repaired is through this deterministic homologous repair route."

Though it may seem counter-intuitive, one of Nayak and Metcalf's first uses of CRISPR-Cas9 was to introduce an NHEJ mechanism in Methanosarcina acetivorans. Though generally not preferable for genome editing, says Nayak, NHEJ has one use for which it's superior to homologous repair: "If you just want to delete a gene, if you don't care how ... non-homologous end joining is actually more efficient."

By using the introduced NHEJ repair system to perform what are known as "knock-out" studies, wherein a single gene is removed or silenced to see what changes are produced and what processes that gene might affect, Nayak says that future research will be able to assemble a genetic atlas of M. acetivorans and other archaeal species. Such an atlas would be incredibly useful for a variety of fields of research involving Archaea, including an area of particular interest to the Metcalf lab, climate change.

"Methanosarcina acetivorans is the one of the most genetically tractable archaeal strains," says Nayak. "[Methanogens are] a class of archaea that produce gigatons of this potent greenhouse gas every year, play a keystone role in the global carbon cycle, and therefore contribute significantly to global climate change." By studying the genetics of this and similar organisms, Nayak and Metcalf hope to gain not only a deeper understanding of archaeal genetics, but of their role in broader environmental processes.

In all, this research represents an exciting new direction in studying and manipulating archaea. "We began this research to determine if the use of CRISPR-Cas9 genome editing in archaea was even possible," concludes Nayak. "What we've discovered is that it's not only possible, but it works remarkably well, even as compared to eukaryotic systems."

Explore further: Modifying fat content in soybean oil with the molecular scissors Cpf1

More information: Dipti D. Nayak et al, Cas9-mediated genome editing in the methanogenic archaeon, Proceedings of the National Academy of Sciences (2017). DOI: 10.1073/pnas.1618596114

A team from the Center for Genome Engineering, within the Institute for Basic Research (IBS), succeeded in editing two genes that contribute to the fat contents of soybean oil using the new CRISPR-Cpf1 technology: an alternative ...

Although the genome editing system known as CRISPR/Cas has revolutionized genetic research in cell lines, its overall efficiency has been relatively poor when used to generate genetically altered animals for disease modeling. ...

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, ...

Rest easy, folks. Armies of genetically modified super-species are unlikely to conquer Earth anytime soon.

A unique gene-editing method that efficiently inserts DNA into genes located in dividing and non-dividing cells of living rats has been developed by a team of international researchers, including scientists from KAUST.

CRISPR-Cas9 is a powerful new tool for editing the genome. For researchers around the world, the CRISPR-Cas9 technique is an exciting innovation because it is faster and cheaper than previous methods. Now, using a molecular ...

Researchers at the University of Arizona have found a promising way to prevent the loss of millions of tons of crops to a fungus each year, offering the potential to dramatically improve food security, especially in developing ...

Finnish and Estonian researchers have discovered and identified 16 new fungus gnat species in the Amazonia. The diverse gnat species maintain exceptionally rich parasitoid wasp species, which shows the importance of interdependence ...

A team of researchers with members from several institutions in India has found evidence of ostrich relatives living i
n India as far back as 25,000 years ago. In their paper uploaded to the open access site PLOS ONE, the ...

A new mathematical model could help clarify what drove the evolution of large brains in humans and other animals, according to a study published in PLOS Computational Biology.

A global research team has built five new synthetic yeast chromosomes, meaning that 30 percent of a key organism's genetic material has now been swapped out for engineered replacements. This is one of several findings of ...

Led by Tianjin University Professor Ying-Jin Yuan, TJU's synthetic biology team has completed the synthesis of redesigned yeast chromosomes synV and synX with the two studies published in Science on March 10, 2017.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the rest here:
A new tool for genetically engineering the oldest branch of life - Phys.Org

UCLA professor developing potential treatment for spinal cord injuries – Daily Bruin

A UCLA professor is working to develop a treatment for spinal cord injuries, which are currently incurable.

Stephanie Seidlits, assistant professor of bioengineering, will attempt to use biomaterial made out of hyaluronic acid a long chain of sugars in the body to create a treatment that can be injected into spinal cords. Seidlits will conduct the research with students using a $500,000 grant she won March 1.

The prestigious CAREER award, granted by the National Science Foundation, aims to support scholars who effectively integrate research with education. Seidlits plans to use her research as a project for students in Bioengineering 177: Bioengineering Capstone Design next fall.

Alongside Seidlits, students will be able to investigate the effects of hyaluronic acid on spinal cord cell regeneration using an in vitro device. Using the device, researchers will be able to replicate the cell environment of an injured spinal cord and analyze how HA reacts to that environment.

When the spinal cord is injured, HA, a polymer composed of long sugar chains that support tissue structure, breaks down into smaller fragments to initiate healing. The short fragments are supposed to be replaced by longer ones, but sometimes they stay in the spinal cord, causing inflammation that prevents healing, Seidlits said.

Past research has examined whether HA as a biomaterial can reduce scarring from spinal cord injuries, with mixed results. Seidlits said she thinks the difference in fragment lengths could be a cause for the different outcomes. Her research will determine whether she can control how the cells react to short and long fragments of HA to prevent inflammation.

A big problem is that the people doing the chemistry dont account for the fact that the short fragments act differently than long fragments, Seidlits said. They just put them all together.

Seidlits and students will use the engineered device to test the biomaterials effectiveness before eventually testing it in mices spinal cord tissue.

Observing the cells through the device is better than observing them in a petri dish, which is unable to fully predict how the biomaterial impacts spinal cord cell regeneration in humans, she said. This also minimizes use of mice in experiments.

Arshia Ehsanipour, a graduate student researcher in Seidlits lab, said one of the challenges of engineering a biomaterial is integrating the HA gel material with the native spinal cord tissue.

Its a gel consistency, (so) cells have nowhere to crawl in (the spinal cord), Ehsanipour said. My goal is to get it to be more of a sponge so cells can crawl in and interact with the tissue more easily.

Despite these difficulties, Josh Karam, also a graduate student researcher in Seidlits lab, said he hopes their research will be successful.

The research were doing in the lab, the work were aiming for, is impactful because spinal cord injury is a neurodegenerative condition that affects a lot of people, Karam said. Ideally, we create a treatment that helps people to make paralysis a phase rather than a lifestyle.

Seidlits said that if the device they will use to observe the HA chains works well, students in Bioengineering 177 will help publish the research and patent the device.

The rest is here:
UCLA professor developing potential treatment for spinal cord injuries - Daily Bruin

Regenerative Medicine Workshop, Part 21 – Research Horizons

The Regenerative Medicine Workshop at Hilton Head began its third decade with a long and diverse lineup of researchers who presented their latest work on a spacious range of topics, from DNA barcoded technology to strategies to reverse tissue degeneration in rotator cuff injuries.

In other words, the usual dizzying array of up-to-the-minute research from some of the worlds leading scientists and engineers.

But if there was a topical theme to last weeks 21st annual workshop (March 1-4), it was immunology.

The Hilton Head summit has always been a place where you can learn about the great, late breaking innovations in regenerative medicine, says Ned Waller, professor in the Emory University School of Medicine, and a researcher with the Petit Institute for Bioengineering and Bioscience at Georgia Tech. What striking this year is, half the talks are about immunology.

And that suits Waller just fine. He is director of the Division of Stem Cell Transplantation and Immunotherapy at the Winship Cancer Institute of Emory, where he also directs the Bone Marrow and Stem Cell Transplant Center. And his research presentation at Hilton Head was entitled, Another Arrow in the Anti-cancer Quiver: VIP Immunotherapy.

Waller also is one of three co-directors of the Regenerative Engineering and Medicine (REM) research center, a consortium of research institutes in Georgia: Emory, Georgia Tech, and the University of Georgia. REM is one of four organizing partners of the workshop, the others being the Stem Cell and Regenerative Medicine Center at the University of Wisconsin, the Mayo Clinics Center for Regenerative Medicine, and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.

Accordingly, faculty, post-doctoral, and student researchers from those institutions were well represented. But the workshop also drew researchers from across the spectrum and the planet. Among the speakers were Ronald Germain from the National Institutes of Health, and Molly Stevens from Imperial College in London. Rolando Gittens, who earned his Ph.D. in bioengineering at Georgia Tech in 2012 and is now a research scientist at the Institute for Scientific Research and High Technology Services of Panama.

There were also deep-dive presentations from researchers based at Duke, Harvard, Tufts, and Yale universities, among others, and Jeff Hubbell, the Nerem Lecturer from the University of Chicago (who delivered a talk on Biomolecular Engineering in Regenerative Medicine and Immunotherapies).

Steve Stice, as co-director of the REM from the University of Georgia (UGA), the newest member of the consortium, appreciated the geographic range of work that was presented.

One of the nice things this years is that UGA and other institutions are well represented, says Stice, professor and director of the Regenerative Bioscience Center at UGA and a Petit Institute researcher. So its not just Emory and Georgia Tech, its also Mayo, and Wisconsin, and Pittsburgh, and weve brought in speakers from all over. Its really grown and become a highly recommended event in the regenerative medicine community.

Trainees postdocs, grad students, and at least one undergraduate had a chance to present their work, also. First there was the rapid fire presentations (5 minutes) on Thursday afternoon, then a research poster competition that night, featuring 65 different projects on display.

The winning poster came from Daniel Hachim, a grad student at the University of Pittsburgh, whose project is entitled, Unveiling Macrophage Populations and Mechanisms Driving the Better Remodeling Outcomes Associated with Shifting Phenotype in the Host Response Against Biomaterials.

Cheryl San Emeterio, a Ph.D. student at Georgia Tech, has presented posters the last three years at this event, but this was her first rapid fire presentation.

I thought it was flattering and inspiring, to talk among so many distinguished scientists here, says San Emeterio, who does her research in the lab of Ed Botchwey, associate professor in the Wallace H. Coulter Department of Biomedical Engineering (a joint department of Emory and Georgia Tech).

Its great to get my work out there on this scale, and I hope that people are interested and want to discuss it further. And maybe we can form some sort of productive collaboration, adds San Emeterio, whose research is entitled, Age-dependent immune Dysregulation during Repair of Volumetric Muscle Injury.

Standing near her poster for most of the evening was Madeline Smerchansky, a Petit Undergraduate Scholar from Georgia Tech attending her first Hilton Head conference. She saw the opportunity as something of an investment.

This is practice for the future, says Smerchansky, a third-year student.

At least one researcher during the four-day workshop offered a glimpse into the future from a perspective that did not include biomolecular science or immunology. Aaron Levine offered his insights , but not the usual stuff based in biomolecular science or bioengineering. Aaron Levine, associate professor in the School of Public Policy at Georgia Tech and a Petit Institute researcher, delivered a presentation called, Regenerative Medicine in a Time of Policy Uncertainty.

We havent seen a lot of clear signals yet with how the policy environment is going to play out from the current presidential administration, says Levine, who focused his Friday morning talk on, among other things, potential policy drivers for regenerative medicine, such as the 21st Century Cures Act (will it be implemented by this administration, and if so, how much of it?), and the appointment of a commissioner for the Food and Drug Administration (FDA).

The future of the Cures Act may be largely dependent on who the next FDA commissioner is, noted to Arnie Caplan, of Case Western University, during Levines post-talk Q&A session.

Later that evening, it was Caplans turn to take center stage, with Chris Evans of the Mayo Clinic.

They were the main event, you might say. With a backdrop of Caplan and Evans as photo-enhanced boxers, the mood was light for their Friday night debate, entitled, MSCs are Not Stem Cells. Or, as Nerem put it, is an MSC a mesenchymal stem cells, a medical signaling cell, or a mediocre scientific concept.

By all accounts, they verbally fought to a draw. But who knows. Maybe there will be a rematch in 2018, when the Regenerative Medicine Workshop will return to Hilton Head (March 21-24).

CONTACT:

Jerry Grillo Communications Officer II Parker H. Petit Institute for Bioengineering and Bioscience

More:
Regenerative Medicine Workshop, Part 21 - Research Horizons

Anatomy of a masterpiece: 13 reasons why the ‘funniest video of the year’ is pure comedy gold – Telegraph.co.uk

13. The off-camera action

The stage has emptied of three of its players, but that's not to say they've left our mind. Just as you start to imagine the rollicking now being dished out, a child's wail can be heard from behind the wall (O:38in the video). Those kids are suffering for the art they've given us and still Prof Kelly goes on, professional to the end, talking aboutNorth Korea and VX gas and things that surely are not at the forefront of his mind right now.

We salute you, Mr Kelly, and offer astanding ovation to your family. And we hope you understand, as laughter ricochets around the internet, that our joy is not mean-spirited. We're laughing because we can see on screen a reflection of our own families, in all their hilariouschaoticbrilliance.

Perhaps Homer Simpson put it best."It's funny," said the father-of-three, "because it's true."

The rest is here:
Anatomy of a masterpiece: 13 reasons why the 'funniest video of the year' is pure comedy gold - Telegraph.co.uk

Berkeley engineers join $24 million push for craniofacial repair therapies – UC Berkeley

Kevin Healy, professor of bioengineering and materials science and engineering, leads Berkeleys role in a new craniofacial research center, C-DOCTOR.

UC Berkeleyis part ofa California-based, six-university consortium that has beenawarded $12 million by the National Institutes of Healthto develop strategies for treating craniofacial defects, which affect millions of Americans.

The consortium, called the Center for Dental, Oral and Craniofacial Tissue and Organ Regeneration (C-DOCTOR), is a part of a broader $24 million effort to develop resources and strategies for regenerating dental, oral and craniofacial tissues that have been damaged by disease or injury.

Craniofacial defects have devastating effects on patients, both because vital sensory organs and brain are housed in the cranium and because the face is so important to a persons identity. Such defects also can lead to compromised general health.

C-DOCTORs goal isto shepherd new therapies through preliminary studies and into human clinical trials. Funding for C-DOCTOR comes from the NIHs National Institute of Dental and Craniofacial Research (NIDCR).

Kevin Healy, professor in the College of Engineering, leads Berkeleys research efforts inC-DOCTOR. Other C-DOCTOR partners include UC San Francisco, University of Southern California, UC Davis, UCLA and Stanford. C-DOCTOR is seeking to establish industry partnerships, identify important clinical applications and evaluate mature tissue-regeneration technologies.

The College of Engineering has had a long history in the area of tissue engineering and regenerative medicine, Healy said. Faculty in the departments of bioengineering and materials science are at the forefront of cutting-edge research that will have a transformative impact on craniofacial tissue engineering. The C-DOCTOR funding provides the facilities and resources to support their activity, providing what is necessary to explore interdisciplinary collaborations to achieve the translational goals of the center.

For more on how UC Berkeley is working to treat craniofacial disorders, watch the video below about how researchers here have discovered molecules that give hope for treatingTreacher Collins Syndrome.

See the original post here:
Berkeley engineers join $24 million push for craniofacial repair therapies - UC Berkeley

The anatomy of a scheduled loss – Golden State of Mind

Last night, the Golden State Warriors fell to the Boston Celtics (99-86) in the sixth game of a nightmare eight-game stretch that has been dubbed the hardest part of the Warriors schedule. Golden State clearly ran out of gas as Boston dominated the fourth quarter.

To get an idea of what the Warriors have been facing, we take a look at the realities of their grueling itinerary.

After defeating the Brooklyn Nets at home, the Warriors started this killer stretch with a flight across the country to Philadelphia. From there they made their way west to Washington and Chicago, back east to New York, south to Atlanta and back across the country to California for their most recent game against Boston. Theyre now on their way back east to play a back-to-back in Minnesota and then in San Antonio before returning home.

If you do the math on this trip it sounds like a horrible version of The Twelve Days of Christmas: Over 9,500 miles traveled, 10 days, eight games total, seven away, six time zone changes, two sets of back-to-backs sing with me now and a tragic MCL sprain.

Anyone who has traveled over time zones knows it can be an unpleasant experience. You feel groggy, slow and disoriented. This is because your body is telling you that its one time, while your environment is telling you its a completely different time.

We can naturally adjust to this discrepancy as our internal clocks catch up to external environmental clues, but it usually takes a couple days. NBA players have no such luxury. As a result, theyre often forced to play games with their internal clocks out of rhythm. Hardly a recipe for success.

Sleep schedules are often disrupted when traveling across time zones. A 2011 Stanford University study was conducted on eleven members of the Stanford mens basketball team. Baseline data was collected on the players while they maintained their typical sleep schedules. Then a period of extended sleep was instituted where the subjects would get at least 10 hours of sleep per night.

Impressively, with the increase in sleep, the subjects also had faster reaction times and faster sprint times. They also had, get this, an increase in free-throw and three-point shooting percentages of nine percent.

Unfortunately, lack of sleep can have essentially the opposite effect on performance. So traveling across the country while playing an intense sport on the biggest stage is going to take its toll, to say the least.

Obviously, the act of playing basketball is itself a tall task. Players will run over three miles during the course of a game, mostly at a dead sprint. On average, a player will have 1,000 changes of movement patterns per game each change occurring about every two seconds all from explosive bursts from their muscles.

Along with the physical aspects of the sport comes the mental fatigue. Being locked in and engaged during a game takes a significant amount of mental energy.

Not to mention that the Warriors are one of the most scrutinized teams in the league right now and every move, good or bad, is analyzed to death. The players know this better than anyone; and while they might not care what anyone else thinks, that doesnt mean it doesnt take mental fortitude to deal with all the talk.

Given the difficulty of this stretch of games, the result of last nights game against the Celtics shouldnt come as a huge surprise. So far, theyre 3-3 since the start of their most recent road trip 2-3 since losing Durant and with a back-to-back left, the Warriors still have a lot more work to do before they can return home for a nice home stand.

History tells us that in an 82-game season, there are always going to be scheduled losses. I mean, the game against the San Antonio Spurs has scheduled loss written all over it! But the reality is that every team has a killer stretch of games at some point during the season and they just have to deal with it. For the Warriors, that time is now. Its just unfortunate that it has coincided with the loss of a key player, but thats the NBA.

You can chalk it up to the schedule, to the grind, to fatigue or to any other reason, but in the end, a loss is a loss. All the Warriors can do is look to the next game and work on getting better.

Yes, theyre tired. Yes, theyre a man down. And, yes, theyre not playing very well at the moment. So, as a fan, its sometimes hard to watch. But Klay Thompson put it best when he said this:

Eyes on the prize, people.

Lets go Dubs.

Read the original here:
The anatomy of a scheduled loss - Golden State of Mind

Gene editing opens the door to a revolution in treating and preventing disease – Yale News

March 8, 2017

Today, in vitro fertilization provides a way for couples to avoid passing potentially disease-causing genes to their offspring. A couple will undergo genetic screening. Tests will determine whether their unborn children are at risk. If embryos created through IVF show signs of such a genetic mutation, they can be discarded.

Flash forward a few years, and, instead of being discarded, those embryos can be repaired with new gene editing technologies. And those repairs will affect not only those children, but all their descendants

This is definitely new territory, said Pasquale Patrizio, M.D., director of the Yale Fertility Center and Fertility Preservation Program. We are at the verge of a huge revolution in the way disease is treated.

We are at the verge of a huge revolution in the way disease is treated.

In a move that seems likely to help clear the path for the use of gene editing in the clinical setting, on February 14 the Committee on Human Gene Editing, formed by the National Academy of Medicine and the National Academy of Sciences, recommended that research into human gene editing should go forward under strict ethical and safety guidelines. Among their concerns were ensuring that the technology be used to treat only serious diseases for which there is no other remedy, that there be broad oversight, and that there be equal access to the treatment. These guidelines provide a framework for discussion of technology that has been described as an ethical minefield and for which there is no government support in the United States.

A main impetus for the committees work appears to be the discovery and widespread use of CRISPR-Cas9, a defense that bacteria use against viral infection. Scientists including former Yale faculty member Jennifer Doudna, Ph.D., now at the University of California, Berkeley, and Emmanuelle Charpentier, Ph.D., of the Max Planck Institute for Infection Biology in Berlin, discerned that the CRISPR enzyme could be harnessed to make precision cuts and repairs to genes. Faster, easier, and cheaper than previous gene editing technologies, CRISPR was declared the breakthrough of the year in 2015 by Science magazine, and has become a basic and ubiquitous laboratory research tool. The committees guidelines, said scientists, physicians, and ethicists at Yale, could pave the way for thoughtful and safe use of this and other human gene editing technologies. In addition to CRISPR, the committee described three commonly used gene editing techniques; zinc finger nucleases, meganucleases, and transcription activator-like effector nucleases.

Patrizio, professor of obstetrics, gynecology, and reproductive sciences, said the guidelines are on the mark, especially because they call for editing only in circumstances where the diseases or disabilities are serious and where there are not alternative treatments. He and others cited such diseases as cystic fibrosis, sickle cell anemia, and thalassemia as targets for gene editing. Because they are caused by mutations in a single gene, repairing that one gene could prevent disease.

Peter Glazer, M.D. 87, Ph.D. 87, HS 91, FW 91, chair and the Robert E. Hunter Professor of Therapeutic Radiology and professor of genetics, said, The field will benefit from guidelines that are thoughtfully developed. This was a step in the right direction.

The panel recommended that gene editing techniques should be limited to deal with genes proven to cause or predispose to specific diseases. It should be used to convert mutated genes to versions that are already prevalent in the population. The panel also called for stringent oversight of the process and for a prohibition against use of the technology for enhancements, rather than to treat disease. As physicians, we understand what serious diseases are. Many of them are very well known and well characterized on a genetic level, Glazer said. The slippery slope is where people start thinking about modifications in situations where people dont have a serious disorder or disease.

Mark Mercurio, M.D., professor of pediatrics (neonatology), and director of the Program for Biomedical Ethics, echoed that concern. While he concurs with the panels recommendations, he urged a clear definition of disease prevention and treatment. At some point we are not treating, but enhancing. This in turn, he said, conjures up the nations own medical ethical history, which includes eugenics policies in the early 20th century that were later adopted in Nazi Germany. This has the potential to help a great many people, and is a great advance. But we need to be cognizant of the history of eugenics in the United States and elsewhere, and need to be very thoughtful in how we use this technology going forward, he said.

The new technology, he said, can lead to uncharted ethical waters. Pediatric ethics are more difficult, Mercurio said. It is one thing to decide for yourselfis this a risk Im willing to takeand another thing to decide for a child. It is another thing still further, which we have never had to consider, to decide for future generations.

Myron Genel, M.D., emeritus professor of pediatrics and senior research scientist, served on Connecticuts stem cell commission and four years on the Health and Human Services Secretary's Advisory Committee on Human Research Protections. He believes that Connecticuts guidelines on stem cell research provide a framework for addressing the issues associated with human gene editing. There is a whole regulatory process that has been evolved governing the therapeutic use of stem cells, he said. There are mechanisms that have been put in place for effective local oversight and national oversight for stem cell research.

Although CRISPR has been the subject of a bitter patent dispute between Doudna and Charpentier and The Broad Institute in Cambridge, Mass., a recent decision by the U.S. Patent Trial and Appeal Board in favor of Broad is unlikely to affect research at Yale and other institutions. Although Broad, an institute of Harvard and the Massachusetts Institute of Technology, can now claim the patent, universities do not typically enforce patent rights against other universities over research uses.

At Yale, scientists and physicians noted that gene editing is years away from human trials, and that risks remain. The issue now, said Glazer, is How do we do it safely? It is never going to be risk-free. Many medical therapies have side effects and we balance the risks and benefits. Despite its effectiveness, CRISPR is also known for whats called off-target risk, imprecise cutting and splicing of genes that could lead to unforeseen side effects that persist in future generations. CRISPR is extremely potent in editing the gene it is targeting, Glazer said. But it is still somewhat promiscuous and will cut other places. It could damage a gene you dont want damaged.

Glazer has been working with a gene editing technology called triple helix that hijacks DNAs own repair mechanisms to fix gene mutations. Triple helix, as its name suggests, adds a third strand to the double helix of DNA. That third layer, a peptide nucleic acid, binds to DNA and provokes a natural repair process that copies a strand of DNA into a target gene. Unlike CRISPR and other editing techniques, it does not use nucleases that cut DNA. This just recruits a process that is natural. Then you give the cell this piece of DNA, this template that has a new sequence, Glazer said, adding that triple helix is more precise than CRISPR and leads to fewer off-target effects, but is a more complex technology that requires advanced synthetic chemistry.

Along with several scientists across Yale, Glazer is studying triple helix as a potential treatment for cystic fibrosis, HIV/AIDS, spherocytosis, and thalassemia.

Adele Ricciardi, a student in her sixth year of the M.D./Ph.D. program, is working with Glazer and other faculty on use of triple helix to make DNA repairs in utero. She also supports the panels decision, but believes that more public discussion is needed to allay fears of misuse of the technology. In a recent presentation to her lab mates, she noted that surveys show widespread public concern about such biomedical advances. One study found that most of those surveyed felt it should be illegal to change the genes of unborn babies, even to prevent disease.

There is, I believe, a misconception of what we are using gene editing for, Ricciardi said. We are using it to edit disease-causing mutations, not to improve the intelligence of our species or get favorable characteristics in babies. We can improve quality of life in kids with severe genetic disorders.

This article was submitted by John Dent Curtis on March 8, 2017.

See the rest here:
Gene editing opens the door to a revolution in treating and preventing disease - Yale News

McGill ranked world’s 3rd best university for study of Anatomy & Physiology – McGill Newsroom

McGill University is the worlds third-best university for the study of Anatomy & Physiology, behind only the Universities of Oxford and Cambridge, according to the 2017 QS World University Rankings by Subject.

The seventh edition of QS Quacquarelli Symondss analysis of subject-specific university performance, released today, lists the worlds best universities for the study of 46 different subjects. Anatomy & Physiology is one of four new subject categories introduced in this years listing.

We are extremely pleased to rank among the worlds top three universities in the study of anatomy and physiology, said David Eidelman, Vice-Principal of Health Affairs and Dean of Medicine at McGill. This is a direct outcome of the quality of our academics and staff in these departments, who I congratulate for their stellar and hard work on behalf of our students. I am also gratified to see McGills rankings rise this year in the medicine and pharmacology categories.

McGills ranking in the Medicine subject category rose to 22nd this year from 27th in 2016. In Pharmacology, McGill moved up to the 31st spot from 37th a year ago.

Another standout performance came in the Engineering Mineral and Mining category, with McGill rising to a tie for sixth place globally this year from 13th place last year. We are very proud to be ranked so highly along with our counterparts in other Canadian institutions, said Jim Nicell, McGills Dean of Engineering. The mining industry is an essential part of the economy of Canada, so we must always do our best to stay at the forefront in our teaching and research in support of this sector.

More broadly, McGill is listed this year in the top 50 in 7 of 10 subjects in Arts & Humanities, 3 of 6 subjects in Engineering & Technology, 7 of 9 in Life Sciences & Medicine, 6 of 7 in Natural Sciences, and 9 of 14 in Social Sciences & Management.

The full QS World University Rankings by Subject tables can be foundhere. The full methodology can be foundhere.

Read this article:
McGill ranked world's 3rd best university for study of Anatomy & Physiology - McGill Newsroom

Transcrypt: Anatomy of a Python to JavaScript Compiler – InfoQ.com

Key Takeaways

Featuring a diversity of programming languages, backend technology offers the right tool for any kind of job. At the frontend, however, it's one size fits all: JavaScript. Someone with only a hammer will have to treat anything like a nail. One attempt to break open this restricted world is represented by the growing set of source to source compilers that target JavaScript. Such compilers are available for languages as diverse as Scala, C++, Ruby, and Python. The Transcrypt Python to JavaScript compiler is a relatively new open source project, aiming at executing Python 3.6 at JavaScript speed, with comparable file sizes.

For a tool like this to offer an attractive alternative to everyday web development in JavaScript, at least the following three demands have to be met:

To be successful, all aspects of these three requirements have to be met. Different compilers strike a different balance between them, but no viable compiler for every day production use can neglect any of them. For Transcrypt, each of the above three points has led to certain design decisions.

Demand 1:

Look and feel of web sites and web applications are directly connected to the underlying JavaScript libraries used, so to have exactly the same look and feel, a site or application should use exactly the same libraries.

Although fast connections may hide the differences, achieving the same page load time, even on mobile devices running on public networks, mandates having roughly the same code size. This rules out downloading a compiler, virtual machine or large runtime at each new page load.

Achieving the same startup time as pages utilizing native JavaScript is only possible if the code is statically precompiled to JavaScript on the server. The larger the amount of code needed for a certain page, the more obvious the difference becomes.

To have the same sustained speed, the generated JavaScript must be efficient. Since JavaScript virtual machines are highly optimized for common coding patterns, the generated JavaScript should be similar to handwritten JavaScript, rather than emulating a stack machine or any other low level abstraction.

Demand 2:

To allow seamless access to any JavaScript library, Python and JavaScript have to use unified data formats, a unified calling model, and a unified object model. The latter requires the JavaScript prototype based single inheritance mechanism to somehow gel with Pythons class based multiple inheritance. Note that the recent addition of the keyword 'class' to JavaScript has no impact on the need to bridge this fundamental difference.

To enable efficient debugging, things like setting breakpoints and single stepping through code have to be done on the source level. In other words: source maps are necessary. Whenever a problem is encountered it must be possible to inspect and comprehend the generated JavaScript to pinpoint exactly what's going on. To this end, the generated JavaScript should be isomorphic to the Python source code.

The ability to capitalize on existing skills means that the source code has to be pure Python, not some syntactic variation. A robust way to achieve this is to use Python's native parser. The same holds for semantics, a requirement that poses practical problems and requires introduction of compiler directives to maintain runtime efficiency.

Demand 3:

Continuity is needed to protect investments in client side Python code, requiring continued availability of client side Python compilers with both good conformance and good performance. Striking the right balance between these two is the most critical part of designing a compiler.

Continued availability of trained Python developers is sufficiently warranted by the fact that Python has been the number 1 language taught in introductory computer science courses for three consecutive years now. On the backend it is used for every conceivable branch of computing. All these developers, used to designing large, long lived systems rather than insulated, short lived pieces of frontend script code, become available to browser programming if it is done in Python.

With regard to productivity, many developers that have made the switch from a different programming language to Python agree that it has significantly increased their output while retaining runtime performance. The latter is due to the fact that libraries used by Python applications for time critical operations like numerical processing and 3D graphics usually compile to native machine code.

The last point openness to changed needs means that modularity and flexibility have to be supported at every level. The presence, right from the start, of class-based OO with multiple inheritance and a sophisticated module and package mechanism has contributed to this. In addition, the possibility to use named and default parameters allows developers to change call signatures in a late stage without breaking existing code.

Conformance versus performance: language convergence to the rescue

Many Python constructs closely match JavaScript constructs, especially when translating to newer versions of JavaScript. There's a clear convergence between both languages. Specifically, more and more elements of Python make their way into JavaScript: for ... of ..., classes (in a limited form), modules, destructuring assignment and argument spreading. Since constructs like for ... of ... are highly optimized on modern JavaScript virtual machines, it's advantageous to translate such Python constructs to closely matching JavaScript constructs. Such isomorphic translation will result in code that can benefit from optimizations in the target language. It will also result in JavaScript code that is easy to read and debug.

Although with Transcrypt, through the presence of source maps, most debugging will take place stepping through Python rather than JavaScript code, a tool should not conceal but rather reveal the underlying technology, granting developer full access to 'what's actually going on'. This is even more desirable since native JavaScript code can be inserted at any point in the Python source, using a compiler directive.

The isomorphism between Python and the JavaScript code generated by Transcrypt is illustrated by the following fragment using multiple inheritance.

translates to:

Striving for isomorphic translation has limitations, rooted in subtle, but sometimes hard to overcome differences between the two languages. Whereas Python allows lists to be concatenated with the + operator, isomorphic use of this operator in JavaScript result in both lists being converted to strings and then glued together. Of course a + b could be translated to __add__ (a, b), but since the type of a and b is determined at runtime, this would result in a function call and dynamic type inspection code being generated for something as simple as 1 + 1, resulting in bad performance for computations in inner loops. Another example is Python's interpretation of 'truthyness'. The boolean value of an empty list is True (or rather: true) in JavaScript and False in Python. Dealing with this globally in an application would require every if-statement to feature a conversion, since in the Python construct if a: it cannot be predicted whether a holds a boolean or somthing else like a list So if a: would have to be translated to if( __istrue__ (a)), again resulting in slow performance if used in inner loops.

In Transcrypt, compiler directives embedded in the code (pragmas) are used control compilation of such constructs locally. This enables writing matrix computations using standard mathematics notation like M4 = (M1 + M2) * M3, at the same time not generating any overhead for something like perimeter = 2 * pi * radius. Syntactically, pragma's are just calls to the __pragma__ function, executed compile time rather than run time. Importing a stub module containing def __pragma__ (directive, parameters): pass allows this code to run o
n CPython as well, without modification. Alternatively, pragmas can be placed in comments.

Unifying the type system while avoiding name clashes

Another fundamental design choice for Transcrypt was to unify the Python and the JavaScript type system, rather than have them live next to each other, converting between them on the fly. Data conversion costs time and increases target code size as well as memory use. It burdens the garbage collector and makes interaction between Python code and JavaScript libraries cumbersome.

So the decision was made to embrace the JavaScript world, rather than to create a parallel universe. A simple example of this is the following code using the Plotly.js library:

Apart from the pragma allowing to leave out the quotes from dictionary keys, which is optional and only used for convenience, the code looks a lot like comparable JavaScript code. Note the (optional) use of list comprehensions, a facility JavaScript still lacks. The fact that Python dictionary literals are mapped to JavaScript object literals is of no concern to the developer; they can use the Plotly JavaScript documentation while writing Python code. No conversion is done behind the scenes. A Transcrypt dict IS a JavaScript object, in all cases.

In unifying the type systems, name clashes occur. Python and JavaScript strings both have a split (), but their semantics have important differences. There are many cases of such clashes and, since both Python and JavaScript are evolving, future clashes are to be expected.

To deal with these, Transcrypt supports the notion of aliases. Whenever in Python .split is used, this is translated to .py_split, a JavaScript function having Python split semantics. In native JavaScript code split will refer to the native JavaScript split function as it should. However, the JavaScript native split method can also be called from Python, where it is called js_split. While methods like these predefined aliases are available in Transcrypt, the developer can define new aliases and undefine existing ones. In this way any name clashes resulting from the unified type system can be resolved without run time penalty, since aliases do their work compile time.

Aliases also allow generation of any JavaScript identifier from a Python identifier. An example is the $ character, that is allowed as part of a name in JavaScript but forbidden in Python. Transcrypt strictly conforms Python syntax and is parsed by the native CPython parser, making its syntax identical. A piece of code using JQuery may look as follows:

Since Transcrypt uses compilation rather than interpretation, imports have to be decided upon compile time, to allow joined minification and shipment of all modules involved. To this end C-style conditional compilation is supported, as can be seen in the following code fragment:

The same mechanism is used in the Transcrypt runtime to switch between JavaScript 5 and JavaScript 6 code:

In this way optimizations in newer JavaScript versions are taken into account, retaining backward compatibility. In some cases, the possibility for optimization is preferred over isomorphism:

Some optimizations are optional, such as the possibility to activate call caching, resulting in repeated calls to inherited methods being done directly, rather than through the prototype chain.

Static versus dynamic typing: Scripting languages growing mature

There has been a resurgence in appreciation of the benefits of static typing, with TypeScript being the best known example. In Python, as opposed to JavaScript, static typing syntax is an integral part of the language and supported by the native parser. Type checking itself, however, is left to third party tools, most notably mypy, a project from Jukka Lehtosalo with regular contributions of Python initiator Guido van Rossum. To enable efficient use of mypy in Transcrypt, the Transcrypt team contributed a lightweight API to the project, that makes it possible to activate mypy from another Python application without going through the operating system. Although mypy is still under development, it already catches an impressive amount of typing errors at compile time. Static type checking is optional and can be activated locally by inserting standard type annotations. A trivial example of the use of such annotations is the mypy in-process API itself:

As illustrated by the example, static typing can be applied where appropriate, in this case in the signature of the run function, since that is the part of the API module that can be seen from the outside by other developers. If anyone misinterprets the parameter types or the return type of the API, mypy will generate a clear error message, referring to the file and line number where the mismatch occurs.

The concept of dynamic typing remains central to languages like Python and JavaScript, because it allows for flexible data structures and helps to reduce the amount of source code needed to perform a certain task. Source code size is important, because to understand and maintain source code, the first thing that has to happen is to read through it. In that sense, 100 kB of Python source code offers a direct advantage over 300 kB of C++ source that has the same functionality, but without the hard to read type definitions using templates, explicit type inspection and conversion code, overloaded constructors and other overloaded methods, abstract base classes to deal with polymorphic data structures and type dependent branching.

For small scripts well below 100kB source code and written by one person, dynamic typing seems to only have advantages. Very little planning and design are needed; everything just falls into place while programming. But when applications grow larger and are no longer built by individuals but by teams, the balance changes. For such applications, featuring more than roughly 200kB source code, the lack of compile time type checking has the following consequences:

An interface featuring even one parameter that may refer to a complex, dynamically typed object structure, cannot be considered sufficiently stable to warrant separation of concerns. While this type of 'who did what, why and when' programming accounts for tremendous flexibility, it also accounts for design decisions being postponed to the very last, impacting large amounts of already written code, requiring extensive modifications.

The 'coupling and cohesion' paradigm applies. It's OK for modules to have strong coupling of design decisions on the inside. But between modules there should preferably be loose coupling, a design decision to change the inner workings of one module should not influence the others. In general, this leads to the following rules of the thumb for the choice between dynamic and static typing.

So while the current surge in static typing may seem like a regression, it isn't. Dynamic typing has earned its place and it won't go away. The opposite is also true: even a traditionally statically typed language like C# has absorbed dynamic typing concepts. But with the complexity of applications written in languages like JavaScript and Python growing, effective modularization, cooperation and unit validation strategies gain importance. Scripting languages are coming of age.

Why choose Python over JavaScript on the client?

Due to the immense popularity of programming for the web, JavaScript has drawn lots of attention and investment. There are clear advantages in having the same language on the client and on the server. An important advantage is that it becomes possible to move code from server to client in a late stage, when an application is upscaled.

Another advantage is unity of concept, allowing developers to work both on the front end and the back and without constantly switching between technologies. The desirability of decreasing the conceptual distance between the client and server part of an application has resulted in the popularity of a platform like Node.
js. But at the same time, it carries the risk of expanding the 'one size fits all' reality of current web client programming to the server. JavaScript is considered a good enough language by many. Recent versions finally start to support features like class based OO (be it in the form of a thin varnish over its prototyping guts), modules and namespaces. With the advent of TypeScript, the use of strict typing is possible, though incorporating it in the language standard is probably some years away.

But even with these features, JavaScript isn't going to be the one language to end all languages. A camel may resemble a horse designed by a committee, but it never becomes one. What the browser language market needs, in fact what any free market needs, is diversity. It means that the right tool can be picked for the job at hand. Hammers for nails, and screwdrivers for screws. Python was designed with clean, concise readability in mind right from the start. The value of that shouldn't be underestimated.

JavaScript will probably be the choice of the masses in programming the client for a long time to come. But for those who consider the alternative, what matters to continuity is the momentum behind a language, as opposed to an implementation of that language. So the most important choice is not which implementation to use, but which language to choose. In that light Python is an effective and safe choice. Python has a huge mindshare and there's a growing number of browser implementations for it, approaching the golden standard of CPython closer and closer while retaining performance.

While new implementations may supersede existing ones, this process is guided by a centrally guarded consensus over what the Python language should entail. Switching to another implementation will always be easier than switching to the next JavaScript library hype or preprocessor with proprietary syntax to deal with its shortcomings. Looking at the situation in the well-established server world, it is to be expected that multiple client side Python implementations will continue to exist side by side in healthy competition. The winner here is the language itself: Python in the browser is there to stay.

Jacques de Hooge MSc is a C++/Python developer living in Rotterdam, the Netherlands. After graduating from the Delft University of Technology, department of Information Theory, he started his own company, GEATEC engineering, specializing in Realtime Controls, Scientific Computation, Oil and Gas Prospecting and Medical Imaging.He is a part-time teacher at the Rotterdam University of Applied Sciences, where he teaches C++, Python, Image Processing, Artificial Intelligence, Robotics, Realtime Embedded Systems and Linear Algebra. Currently he's developing cardiological research software for the Erasmus University in Rotterdam. Also he is the initiator and the lead designer of the Transcrypt open source project.

Here is the original post:
Transcrypt: Anatomy of a Python to JavaScript Compiler - InfoQ.com

Scott Foley’s ‘dead head’ freaks out his wife on Grey’s Anatomy – TV3.ie

9th Mar 17 | Entertainment News

Scott Foley's actress wife freaked out when she saw her first 'dead body' on Grey's Anatomy, because her husband was looking up at her.

Marika Dominczyk has started work on the medical drama that once featured her man as Henry Burton, and she didn't realise the show's prop team recycle Scott's dead head whenever they need a corpse.

"They not so kindly killed me off," he recalls, "but to do so, they made a full prosthesis of my head, and those things are expensive to make, so they don't make a bunch of them.

"Every time they have a dead body or a cadaver laying on a table, it's my head... The first time she had no idea; they didn't tell her... She was like, 'Oh God!'"

Marika, who plays lesbian Dr. Eliza Minnick on the current season of the show, has just returned to acting after taking time off to focus on being a mum to her three kids with Foley. She previously featured in TV drama North Shore and played Bernadette in The 40-Year-Old Virgin.

"She spent seven years raising our children and now that she had the opportunity to go back to work she was really chomping at the bit," Foley tells Access Hollywood Live. "This part came along and she's knocking it out the park... She looks great in a doctor's coat."

But he's not looking forward to sitting down with his wife's TV lover, Jessica Capshaw, and her husband now the old friends are kissing on TV.

"We've known socially Jessica Capshaw and her husband Christopher Gavigan for years, so it was a little strange for them," he explains. "I don't think we've had the chance to talk about it yet. That'll be an interesting conversation."

WENN Newsdesk 2017

Read more here:
Scott Foley's 'dead head' freaks out his wife on Grey's Anatomy - TV3.ie

Study identifies best exercise to reverse signs of aging – Fox News

You already know working out regularly can help keep you slim, boost your mood, aid your sleep, and even stave off disease. But a new study has identified a potential mode of exercise that may help optimize the reversal of any unwanted signs of aging high-intensity interval training (HIIT).

The idea is that instead of long, steady movement (think: running several miles on a treadmill at the same speed and incline), alternating between quick spurts of intense, all-out exercise and lower-intensity exercise during HIIT can help raise your heart rate and enable you to shed more fat, faster.

CAN EATING LESS HELP REDUCE SIGNS OF AGING?

In the new study, published Tuesday in Cell Metabolism, researchers found HIIT in aerobic exercises like biking and walking revved cells ability to generate more proteins within mitochondria and their protein-building ribosomes essentially stunting aging at a cellular level.

"Based on everything we know, there's no substitute for these exercise programs when it comes to delaying the aging process," senior study author Sreekumaran Nair, a medical doctor and diabetes researcher at the Mayo Clinic in Rochester, Minnesota, said in a news release. "These things we are seeing cannot be done by any medicine."

Researchers enrolled 36 men and 36 women from a younger group (ages 18 to 30) and an older group (ages 65 to 80). Each group received a different exercise assignment: either high-intensity interval biking, strength training with weights, or a regimen that combined strength training and HIIT.

7 WRINKLE-FIGHTING FOODS PROBABLY ALREADY IN YOUR KITCHEN

Next, they biopsied participants thigh muscles and compared their molecular makeup against those of sedentary volunteers. They also analyzed the participants lean muscle mass and insulin sensitivity, which is a marker for type 2 diabetes.

They found strength training aided muscle building, but the younger group that did HIIT saw a 49 percent increase in mitochondrial capacity and the older group saw a 69 percent increase. HIIT also helped reduce insulin sensitivity.

FOLLOW US ON FACEBOOK FOR MORE LIFESTYLE NEWS

The one thing HIIT wasnt good for? Building muscle. Thats why a mix of HIIT and strength training may offer the most benefits, as muscle mass tends to decline with aging, Nair noted.

"If people have to pick one exercise, I would recommend high-intensity interval training, Nair said in the release, but I think it would be more beneficial if they could do 3-4 days of interval training and then a couple days of strength training.

See the original post here:
Study identifies best exercise to reverse signs of aging - Fox News